AACR 2026 Poster | Targeted radionuclide therapy (TRT) with alpha and beta emitters provides a precise cancer treatment approach that improves outcomes while limiting systemic toxicity.
The development of new radiopharmaceuticals relies on robust in vitro and in vivo assays to assess target specificity, pharmacokinetics, biodistribution, resistance mechanisms, and therapeutic index.
Our results show that combining radiochemistry expertise with clinically relevant patient-derived models improves characterisation of novel radiopharmaceuticals and strengthens the predictive power of preclinical studies, ensuring new therapies align with clinical needs.
Meet the team at AACR 2026 at Booth 1418, Hall C (Ground Level).
View the poster here
PACE (Pathways to Antimicrobial Clinical Efficacy) and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns.
New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.
Dr Emma Jones, a Lead Scientist in in vitro Neurobiology at Medicines Discovery Catapult (MDC), has contributed to a new children’s book celebrating the diversity of careers in science.
